NCT07643766
A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Not Yet Recruiting
PHASE2Ages 18+InterventionalTreatmentEnveda Therapeutics
~200 participants
Updated 2026-06-12 on ClinicalTrials.gov
What's tested:ENV-294Placebo
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent change in Eczema Area and Severity Index (EASI) score
Measured over Baseline to Week 12
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Study leadership
- Gurpreet Ahluwalia, PhD · STUDY_DIRECTOR · Enveda Therapeutics, Inc.
Who to contact
Clinical Operations
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Percent change in Eczema Area and Severity Index (EASI) scoreBaseline to Week 12